Big regulatory events for July include a panel for Fibrogen's roxadustat and decision time for Albireo; elsewhere, Jak inhibitor delays could persist.
At the US liver conference Inventiva will make a case for PPAR agonism, while Novo Nordisk and Gilead’s combo will be scrutinised in Nash.
Mirum has it all to do after Albireo gets a result with lead project odevixibat in a rare childhood liver disease.
Companies formed around unwanted big pharma assets have a mixed record, although some parents are better at finding spinouts than others.
Our final look at third-quarter events focuses this time on the smallest players, with data from Amryt, Ovid, Bellus and more.
High-profile presentations from the likes of Intercept and Alnylam remain under wraps before Europe’s biggest liver disease conference next month, but the early abstract…
Albireo is taking aim at yet another Nash target, but Shire and Glaxosmithkline have already ditched projects with similar mechanisms.